{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:22:06Z","timestamp":1777868526977,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2017\\u201320594"],"award-info":[{"award-number":["IG 2017\\u201320594"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PE-2016-02361797"],"award-info":[{"award-number":["PE-2016-02361797"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["2017N8CK4K"],"award-info":[{"award-number":["2017N8CK4K"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.canlet.2020.10.022","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T04:07:33Z","timestamp":1602821253000},"page":"77-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells"],"prefix":"10.1016","volume":"497","author":[{"given":"R.","family":"Catalano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Giardino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Treppiedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mangili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.M.","family":"Elli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Serban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Luconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Spada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Arosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Peverelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2020.10.022_bib1","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in The Netherlands since 1993","volume":"49","author":"Kerkhofs","year":"2013","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.canlet.2020.10.022_bib2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.canlet.2020.10.022_bib3","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.canlet.2020.10.022_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2008.10.008","article-title":"Clinical management of adrenocortical carcinoma","volume":"23","author":"Fassnacht","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.canlet.2020.10.022_bib5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41574-019-0221-7","article-title":"Adrenocortical carcinoma - towards genomics guided clinical care","volume":"15","author":"Crona","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.canlet.2020.10.022_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1530\/EJE-18-0450","article-title":"Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis","volume":"179","author":"Vanbrabant","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.canlet.2020.10.022_bib7","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2020.10.022_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1558","article-title":"Value of molecular classification for prognostic assessment of adrenocortical carcinoma","volume":"5","author":"Assi\u00e9","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canlet.2020.10.022_bib9","first-page":"1444","article-title":"Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors","volume":"78","author":"Gicquel","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2020.10.022_bib10","first-page":"2559","article-title":"Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors","volume":"82","author":"Gicquel","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2020.10.022_bib11","first-page":"1713","article-title":"Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors","volume":"83","author":"Boulle","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2020.10.022_bib12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0002-9440(10)63846-1","article-title":"Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis","volume":"162","author":"Giordano","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2020.10.022_bib13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2559.2006.02505.x","article-title":"IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours","volume":"49","author":"Schmitt","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.canlet.2020.10.022_bib14","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1210\/jc.2004-1075","article-title":"Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy","volume":"90","author":"de Fraipont","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2020.10.022_bib15","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1210\/jc.2008-0065","article-title":"Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors","volume":"93","author":"Almeida","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2020.10.022_bib16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/jc.2008-1456","article-title":"Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma","volume":"94","author":"Barlaskar","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2020.10.022_bib17","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1530\/ERC-15-0086","article-title":"Copy number variations alter methylation and parallel IGF2 overexpression in adrenal tumors","volume":"22","author":"Nielsen","year":"2015","journal-title":"Endocr. Relat. Canc."},{"key":"10.1016\/j.canlet.2020.10.022_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044171","article-title":"Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models","volume":"7","author":"Drelon","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2020.10.022_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103744","article-title":"IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma","volume":"9","author":"Guillaud-Bataille","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2020.10.022_bib20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12020-019-01869-1","article-title":"IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer","volume":"64","author":"De Martino","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.canlet.2020.10.022_bib21","first-page":"83","article-title":"Immunoreactivity and receptor expression of insulin like growth factor I and insulin in human adrenal tumors. An immunohistochemical study of 94 cases","volume":"138","author":"Kamio","year":"1991","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2020.10.022_bib22","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s00018-013-1514-y","article-title":"Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signalling regulation","volume":"71","author":"Girnita","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.canlet.2020.10.022_bib23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2020.10.022_bib24","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1530\/ERC-18-0442","article-title":"Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors","volume":"26","author":"Mantovani","year":"2019","journal-title":"Endocr. Relat. Canc."},{"key":"10.1016\/j.canlet.2020.10.022_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1530\/ERC-15-0358","article-title":"Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours","volume":"23","author":"Vitali","year":"2016","journal-title":"Endocr. Relat. Canc."},{"key":"10.1016\/j.canlet.2020.10.022_bib26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12253-015-9980-1","article-title":"Filamin A: insights into its exact role in cancers","volume":"22","author":"Shao","year":"2016","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.canlet.2020.10.022_bib27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4161\/cam.5.2.14401","article-title":"The filamins: organizers of cell structure and function","volume":"5","author":"Nakamura","year":"2011","journal-title":"Cell Adhes. Migrat."},{"key":"10.1016\/j.canlet.2020.10.022_bib28","doi-asserted-by":"crossref","first-page":"27096","DOI":"10.1074\/jbc.M301003200","article-title":"Interaction of filamin A with the insulin receptor alters insulin-dependent activation of the mitogen-activated protein kinase pathway","volume":"278","author":"He","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2020.10.022_bib29","doi-asserted-by":"crossref","first-page":"17823","DOI":"10.7554\/eLife.17823","article-title":"Upregulation of neurovascular communication through filamin abrogation promotes ectopic periventricular neurogenesis","volume":"5","author":"Houlihan","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.canlet.2020.10.022_bib30","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1210\/en.2014-1063","article-title":"Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells","volume":"155","author":"Peverelli","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2020.10.022_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2337\/db17-0321","article-title":"Clec16a, Nrdp1, and USP8 form a ubiquitin-dependent tripartite complex that regulates \u03b2-cell mitophagy","volume":"67","author":"Pearson","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.canlet.2020.10.022_bib32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.canlet.2009.06.034","article-title":"The dopamine\u2010somatostatin chimeric compound BIM\u201023A760 exerts antiproliferative and cytotoxic effects in human non\u2010functioning pituitary tumors by activating ERK1\/2 and p38 pathways","volume":"288","author":"Peverelli","year":"2010","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2020.10.022_bib33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1530\/ERC-11-0270","article-title":"The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells","volume":"19","author":"De Martino","year":"2012","journal-title":"Endocr. Relat. Canc."},{"key":"10.1016\/j.canlet.2020.10.022_bib34","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/1535-7163.MCT-10-0318","article-title":"Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer","volume":"9","author":"Buck","year":"2010","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2020.10.022_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1677\/jme.0.0230023","article-title":"Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line","volume":"23","author":"Logi\u00e9","year":"1999","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.canlet.2020.10.022_bib36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1535-6108(04)00050-9","article-title":"Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors","volume":"5","author":"Mitsiades","year":"2004","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2020.10.022_bib37","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1158\/1078-0432.CCR-14-0303","article-title":"A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors","volume":"21","author":"Puzanov","year":"2015","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.10.022_bib38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1126\/science.1549777","article-title":"Actin-binding protein requirement for cortical stability and efficient locomotion","volume":"255","author":"Cunningham","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.canlet.2020.10.022_bib39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.mce.2011.08.041","article-title":"Human adrenocortical carcinoma cell lines","volume":"351","author":"Wang","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.canlet.2020.10.022_bib40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0955-0674(99)00078-2","article-title":"Signal transduction: hanging on a scaffold","volume":"12","author":"Burack","year":"2000","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.canlet.2020.10.022_bib41","article-title":"Cytoskeleton protein Filamin A is required for efficient Somatostatin receptor type 2 internalization and recycling through Rab 5 and Rab 4 sorting endosomes in tumor somatotroph cells","author":"Treppiedi","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.canlet.2020.10.022_bib42","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1242\/jcs.193821","article-title":"Phosphorylation of filamin A regulates chemokine receptor CCR2 recycling","volume":"130","author":"Pons","year":"2017","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2020.10.022_bib43","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1210\/en.2008-1344","article-title":"Filamin A modulates kinase activation and intracellular trafficking of epidermal growth factor receptors in human melanoma cells","volume":"150","author":"Fiori","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2020.10.022_bib44","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1210\/jc.2011-2902","article-title":"Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs","volume":"97","author":"Peverelli","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2020.10.022_bib45","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4161\/cam.5.2.14401","article-title":"The filamins: organizers of cell structure and function","volume":"5","author":"Nakamura","year":"2011","journal-title":"Cell Adhes. Migrat."},{"key":"10.1016\/j.canlet.2020.10.022_bib46","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/er.2008-0047","article-title":"Insulin receptor isoforms and insulin receptor\/insulin-like growth factor receptor hybrids in physiology and disease","volume":"30","author":"Belfiore","year":"2009","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.canlet.2020.10.022_bib47","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1128\/MCB.19.5.3278","article-title":"Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells","volume":"19","author":"Frasca","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2020.10.022_bib48","first-page":"3671","article-title":"Filamin A regulates EGFR\/ERK\/Akt signaling and affects colorectal cancer cell growth and migration","volume":"20","author":"Wang","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.canlet.2020.10.022_bib49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-11-50","article-title":"Targeting filamin A reduces K-RAS-induced lung adenocarcinomas and endothelial response to tumor growth in mice","volume":"11","author":"Nallapalli","year":"2012","journal-title":"Mol. Canc."},{"issue":"6","key":"10.1016\/j.canlet.2020.10.022_bib50","doi-asserted-by":"crossref","first-page":"R341","DOI":"10.1530\/ERC-13-0364","article-title":"The dual role of filamin A in cancer: can't live with (too much of) it, can't live without it","volume":"20","author":"Savoy","year":"2013","journal-title":"Endocr. Relat. Canc."},{"key":"10.1016\/j.canlet.2020.10.022_bib51","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1038\/onc.2017.179","article-title":"Functional antagonism of \u03b2-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes","volume":"36","author":"Suleymanova","year":"2017","journal-title":"Oncogene"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520305498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520305498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:04:07Z","timestamp":1777550647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383520305498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":51,"alternative-id":["S0304383520305498"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2020.10.022","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2020.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}